Congress extends Rare Pediatric Disease Priority Review Voucher programme through 2029

Brian Malkin and Sadaf Deedar, Spencer Fane LLP, unpack the recent changes to the FDA’s Priority Review Voucher scheme and the upcoming review of its effectiveness in promoting drug development for rare paediatric diseases. 

Congress recently enacted the Consolidated Appropriations Act, 2026 (CAA), which provided $1.2 trillion in funding for key federal departments through to 30 September of this year. 

Among the health policy provisions, Section 6604 extended the Rare Pediatric Disease Priority Review Voucher (PRV) programme through to 30 September 2029, preserving a regulatory incentive to encourage development of treatments and therapies for children with rare diseases. This restored some predictability for companies in the drug discovery industry but also creates novel considerations for the short and long-term. 

Specifically, Congress also directed the Government Accountability Office (GAO) to conduct a comprehensive study of effectiveness of rare paediatric disease PRVs. This will include a look at what diseases might qualify for the vouchers, which could realistically expand or contract the programme’s reach depending on the outcome. 

Background and purpose of the Rare Pediatric Disease PRV programme 

Congress created the Rare Pediatric Disease PRV programme in 2012 as part of the FDA Safety and Innovation Act to encourage the development of treatments for serious or life-threatening diseases affecting small paediatric populations. 

Under the programme, a sponsor that obtains FDA approval of a drug or biologic for a qualifying rare paediatric disease may receive a transferable voucher entitling the holder to priority review of a future marketing application. Section 529(a)(3) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) defines a “rare paediatric disease” as a serious or life-threatening condition that primarily affects individuals from birth through 18 and qualifies as a “rare disease or condition.” That term is defined in Section 526 of the FD&C Act as one affecting fewer than 200,000 people in the US, or if more prevalent, one for which there is no reasonable expectation that development costs will be recovered through US sales.  

Priority review shortens FDA’s review timeline from the standard 10 months to about six months. Because faster review can significantly accelerate time to market and translate to earlier sales, vouchers have substantial economic value and have sold for more than $100 million in private transactions. 

Sponsors may seek rare paediatric disease designation during development to help establish that a drug or biologic is intended to treat or prevent a qualifying condition. Although designation is not required to receive a voucher, FDA encourages sponsors to request before submitting a marketing application, and applicants must show that the drug or biologic meets the statutory eligibility criteria. 

The programme was designed to address a persistent market failure. 

Many rare paediatric diseases affect only a few thousand patients worldwide, making traditional return-on-investment models difficult to justify. By attaching a transferable asset to approval of a paediatrictherapy, Congress sought to encourage companies to pursue research that might otherwise be financially infeasible. Conditions such as spinal muscular atrophy, sickle cell disease, Batten disease, and autosomal recessive polycystic kidney disease illustrate the types of unmet needs the programme aims to address. 

Since creation, the Rare Pediatric Disease PRV programme has played a meaningful role in paediatric drug development. 

As of late 2025, FDA had awarded more than 60 vouchers covering dozens of rare paediatric diseases, many of which previously lacked any FDA-approved therapies. Industry observers credit the programmewith accelerating development timelines, attracting investment into small-patient-population research, and generating financing through secondary voucher sales. Faster review can bring products to market sooner, improving commercial viability, while the ability to sell a voucher provides an important source of capital for emerging biotechnology companies. 

Section 6604 of the CAA makes two principal statutory changes. 

First, this replaces a prior sunset provision with a new deadline of 30 September 2029. The FDA may continue to award vouchers for qualifying approvals until that date. The statute does not impose a separate deadline for obtaining rare paediatric disease designation, which preserves flexibility for sponsors whose development timelines extend several years. 

Second, the amendment clarifies that the priority review voucher user fee is due upon submission of the marketing application that redeems the voucher, while other applicable user fees continue to follow standard FDA timing. 

GAO Study 

The GAO must examine, among other issues, the types of drugs or biologics that earned vouchers, whether those approvals addressed unmet medical needs, how vouchers have been transferred and used, and whether the programme has influenced drug development decisions, investment in rare paediatric therapies, or FDA review priorities. 

The GAO must report findings to Congress within five years of enactment. The study’s findings may help inform future legislative decisions about whether to extend, modify, or replace the programme after the current authorisation period. 

Practical takeaways 

While the CAA’s extension restores predictability for companies developing therapies for rare paediatric diseases, sponsors can also incorporate the potential value of a priority review voucher into portfolio planning, licensing negotiations, and financing strategies. For companies currently in development, the 2029 sunset provides a clear window for evaluating whether their programmes may qualify. 

At the same time, the mandated GAO review means that the programme will be examined in the coming years. Monitoring the GAO study and the eventual findings will provide key insight into how Congress approaches the programme’s future. 

About the authors 

Brian Malkin streamlines processes for clients navigating the complex intersection of patent law and food and drug law, leveraging unique public and private sector experience, in-depth creative and strategic analysis, and advanced negotiation tactics to meet and exceed stakeholder expectations. 

Sadaf Deedar focuses on patent and trademark prosecution and litigation, as well as internet law and trade secrets. She previously served as a patent administrator for a healthcare technology company and interned at a boutique Atlanta firm, working on patent applications, NDAs, and legal research involving artificial intelligence. 

The post Congress extends Rare Pediatric Disease Priority Review Voucher programme through 2029 appeared first on Drug Discovery World (DDW).